This conference strives to connect industry and academic researchers in the protein therapeutics field to facilitate discussion on the current state of the industry and discuss recent studies and challenges involved in therapeutic development. Representatives from big pharma, academic institutions, and government research labs will present data and case studies on key topics including antibody drug conjugates, bispecific antibodies, antibody combinations, and check-point-inhibiting antibodies.